CHMP announched positive opinion for brigatinib as treatment of ALK positive NSCLC in patients previously treated with crizotinib
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive…
Browsing: anaplastic lymphoma kinase-positive (ALK ) advanced non-small cell lung cancer